Emyria Ltd · ASX:EMD
Emyria — Ignite Investment Summit Singapore 2026
15 slides from Emyria's conference presentation, Apr 21, 2026
Slide 1: Delivering the new paradigm in mental health care
ASX : EMD For personal use only Delivering the new paradigm in mental health care Ignite Investment Summit Singapore April 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. T
Slide 3: Corporate Overview
Corporate Overview Share Price ASX: EMD Trading Information For personal use only Last Traded Share Price A$0.056 12-Month low / high A$0.023 / 0.078 Shares Outstanding 806,483,233 Unlisted Options (including loyalty 310,147,902 options) Market Capitalisation 1 ~A$45m Last Reported Cash Position 2 ~
Slide 4: Globally Mental Health Illness Is a Rising Chronic Health Problem
Globally Mental Health Illness Is a Rising Chronic Health Problem For personal use only Bupa Group CEO - Inaki Ereno “Mental health is the Over a billion people new pandemic but the The global prevalence of living with mental health provision of mental conditions - services mental health disorders i
Slide 5: Significant Global Research in Psychedelic Drugs
Significant Global Research in Psychedelic Drugs More than 50 psychedelic-assisted therapy programs currently in For personal use only development globally1 US President Donald Trump signs Executive Order to fast-track research and patient access to Psyence Biomed psychedelic drugs2 EMD uniquely posi
Slide 6: Australia's Unique Opportunity
Australia’s Unique Opportunity An Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions For personal use only MDMA-assisted therapy Australia for PTSD is the FIRST jurisdiction in Psilocybin-assisted therapy the world to reschedule two promising treatments for
Slide 7: Who is Emyria
Who is Emyria VISION For personal use only To develop and implement a sophisticated, safe model for psychedelic-assisted mental health care - so emerging therapies can be delivered responsibly at scale. 3 1 2 MISSION Emyria is establishing a network of clinics to expand at pace in a capital light fa
Slide 8: Emyria's P-AT Treatment Model
Emyria’s P-AT Treatment Model Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up For personal use only ACTIVE TREATMENT PROTOCOL DOSING DOSING DOSING CYCLE 1 CYCLE 2 CYCLE 3 FOLLOW-UP PERIOD SCREENING AND (12 months from last PREPARATION Dosing Treatment Cycle) Dosing Dosing Day
Slide 9: Emyria's PTSD Program Is Delivering Results
Emyria’s PTSD Program Is Delivering Results Case Study Kate | From “Permanent Disability” To Back at Work MDMA-AT commenced For personal use only 5 years PCL-5 < 30 Kate’s story: First 70 60 responder • PTSD due to cumulative workplace traumas 50 • Myriad of therapies: EMDR, in-vivo, ACT, CBT, PCL-5
Slide 10: Emyria's PTSD Program Is Delivering Durable Results
Emyria’s PTSD Program Is Delivering Durable Results Durable symptom and quality of life improvement, beyond 12 months Average PCL-5 1 Scores by Visit (up to 12 months follow-up) For personal use only Typical last treatment Emyria Real-World Data as of Dec 31st 2025 ~67% of patients no longer meet cr
Slide 11: Emyria Has Developed Significant Scalable Delivery IP and Know How
Emyria Has Developed Significant Scalable Delivery IP and Know How 100+ Trained Secure For personal use only Skilled Drug Supply Clinicians Third Regulatory Party approvals Fundin g Proven Dedicated Clinical Model Facilities 11 Advanced Advancedtherapies. Compassionate therapies. Compassionate care.
Slide 12: Total Addressable Australian Market | PTSD + TRD
Total Addressable Australian Market | PTSD +TRD Adults with difficult to treat PTSD and TRD in Australia For personal use only Australian Adults Australian Adults With PTSD With Major Depression ~1,500,0001 ~1,100,0001 ~7% of all adults ~4% of adults have Major Depressive Disorder ~$33,000 ~$22,000 2
Slide 13: Emyria | Why Invest
Emyria | Why Invest For personal use only Significant Total Operationalised the First mover advantage Addressable Market delivery of PAT at Scale globally globally Capital Light approach Delivering durable Generating revenue to clinics expansion outcomes 13 Advanced therapies. Compassionate care.
Slide 14: Emyria Board
Emyria Board Significant Clinical Services & Global Innovation Expertise For personal use only Greg Hutchinson Dr Michael Winlo Dr Karen Smith Dr Mohit Kaushal Prof Sir John Executive Chairman Executive Director Non-Executive Non-Executive Tooke Director Director Non-Executive Health Service Research
Slide 15: Contact Information
Contact Information For personal use only Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Investor / Visit Our Media Inquiries Investor Hub investors@emyria.com